• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Immunology & Inflammatory Diseases

• Effect of methylthiouracil on the colloidopexic capacity of hepatosplenic macrophages through thyroid function depression.
• Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years.
• Synthesis of small molecule CDC25 phosphatases inhibitors.
• Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases.
• Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.
• Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
• Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.
• Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis.
• Novel antiinflammatory vascular benefits of systemic and stent-based delivery of ethylisopropylamiloride.
• A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.
• A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats.
• BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro.
• Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.
• Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
• Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.
• Inhalation of carbon monoxide prevents liver injury and inflammation following hind limb ischemia/reperfusion.
• Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis.
• Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody.
• Serendipitous discovery of an unexpected rearrangement leads to two new classes of potential protease inhibitors.
• The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.
• Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase.
• Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.
• Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
• Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis.
• Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
• Infliximab treatment for steroid-refractory acute graft-versus-host disease.
• Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
• Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
• Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
• The metabolic syndrome, inflammation, and risk of cognitive decline.
• A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors.
• HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation.
• Ligand discovery using small molecule microarrays.
• Anti-interleukin-12 antibody for active Crohn's disease.
• Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist.
• Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial.
• Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
• Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
• Potential role of heme oxygenase-1 in the progression of rat adjuvant arthritis.
• Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers.
• Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.
• 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
• Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
• Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.
• Pathophysiological role of human beta-defensins 2 in gastric mucosa.
• Antibody-mediated transduction of p53 selectively kills cancer cells.
• Theobromine inhibits sensory nerve activation and cough.
• BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.
• Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.
• Frontline: Inhibition of allergen-induced pulmonary inflammation by the tripeptide feG: a mimetic of a neuro-endocrine pathway.
• Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model.
• IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4+ mucosal T cells in mice.
• Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
• Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure.
• An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice.
• Altered airway responsiveness in CD38-deficient mice.
• Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells.
• Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice.
• A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis.
• NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness.
• Inhibition of fractalkine ameliorates murine collagen-induced arthritis.
• Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis.
• Redirecting the humoral immune response against Streptococcus mutans antigen P1 with monoclonal antibodies.
• Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.
• Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells.
• Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
• IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle.
• Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
• Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
• The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
• Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
• Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling.
• Monoclonal antibody hNM01 in HIV-infected patients: a phase I study.
• Generation of a synthetic lymphoid tissue-like organoid in mice.
• ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
• Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
• Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.
• Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
• Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
• Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization.
• Toll-like receptor 4 or 2 agonists decrease allergic inflammation.
• Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
• Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma.
• Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
• Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma.
• Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis.
• A new NF-kappaB inhibitor attenuates a TH1 type immune response in a murine model.
• Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
• Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.
• 2,3-Diphenylpropionic acids as potent VLA-4 antagonists.
• New cyclooxygenase-2 inhibitor DFU regulates vascular endothelial growth factor expression in rheumatoid synoviocytes.
• Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
• In vivo and in vitro roles of IL-21 in inflammation.
• Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation.
• Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice.
• Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
• 2,3-diaminopyridine bradykinin B1 receptor antagonists.
• Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma.
• Development of the "Cell Chip": a new in vitro alternative technique for immunotoxicity testing.
• Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
• CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis.
• FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation.
• Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.
• A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
• Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.
• CCR4-deficient mice show prolonged graft survival in a chronic cardiac transplant rejection model.
• NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation.
• Assessment of the efficacy of different statins in murine collagen-induced arthritis.
• Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis.
• Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model.
• Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCR1-associated immune responses.
• Synchronized infection of cell cultures by magnetically controlled virus.
• Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
• Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
• CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
• Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity.
• Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
• Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
• Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice.
• Chemokine receptor CCR2 involvement in skeletal muscle regeneration.
• Inflammatory markers and the risk of coronary heart disease in men and women.
• Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists.
• Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme.
• Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
• Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
• The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
• A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice.
• Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
• Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial.
• Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
• Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice.
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
• Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.
• Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
• Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.
• Insertion of an aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptor.
• Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
• Effect of E6060 [4-{5-[7-fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrrolyl}benzoic acid], a novel subtype-selective retinoid, on lupus-like nephritis in female (NZBxNZW)F1 mice.
• {beta}-Cell function following human islet transplantation for type 1 diabetes.
• Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
• Accurate multiplex gene synthesis from programmable DNA microchips.
• Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils.
• Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue.
• Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience.
• Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry.
• Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques.
• A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy.
• Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
• Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
• Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
• Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
• Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
• Lentiviral transduction of microglial cells.
• In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
• Estrogen reduces carbachol-induced constriction of asthmatic airways by stimulating large-conductance voltage and calcium-dependent potassium channels.
• CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease.
• The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation.
• A key role of neurokinin 1 receptors in acute pancreatitis and associated lung injury.
• Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness.
• Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
• Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
• IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins.
• Highly selective inhibition of inducible nitric oxide synthase ameliorates experimental acute pancreatitis.
• A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
• Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
• Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin.
• Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation.
• Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease.
• Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells.
• C-reactive protein levels and outcomes after statin therapy.
• 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice.
• A longitudinal study on an autoimmune murine model of ankylosing spondylitis.
• Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo.
• Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
• Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.
• Reduction of the incidence and severity of collagen-induced arthritis by constitutive Nur77 expression in the T cell lineage.
• Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.
• KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
• Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
• Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice.
• Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031.
• 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.
• Trichostatin A attenuates airway inflammation in mouse asthma model.
• Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent.
• Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
• Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
• Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
• Liposomal methylprednisolone differentially regulates the expression of TNF and IL-10 in human alveolar macrophages.
• Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice.
• CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance.
• Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.
• RNA polymerase IV directs silencing of endogenous DNA.
• Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats.
• Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation.
• Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
• 8-Hydroxyquinoline inhibits iNOS expression and nitric oxide production by down-regulating LPS-induced activity of NF-kappaB and C/EBPbeta in Raw 264.7 cells.
• A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia.
• Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
• Inhibition of scratching behaviour caused by contact dermatitis in histidine decarboxylase gene knockout mice.
• Oral administration of a T cell epitope inhibits symptoms and reactions of allergic rhinitis in Japanese cedar pollen allergen-sensitized mice.
• A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.
• A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
• Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
• Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
• Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
• Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
• Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis.
• Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
• An experimental model of autoimmune pancreatitis in the rat.
• The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
• A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.
• Matricellular homologs in the foreign body response: hevin suppresses inflammation, but hevin and SPARC together diminish angiogenesis.
• Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma.
• Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis.
• Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
• Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
• Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.
• Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.
• Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors.
• Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.
• A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
• Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
• Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
• Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.
• Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.
• Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
• Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
• The chemokine receptor D6 limits the inflammatory response in vivo.
• Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
• Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
• PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
• Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse.
• Association between a variation in the phosphodiesterase 4D gene and bone mineral density.
• Novel TLR4-antagonizing peptides inhibit LPS-induced release of inflammatory mediators by monocytes.
• Engineering of vault nanocapsules with enzymatic and fluorescent properties.
• Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
• Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine.
• Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
• Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
• A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.
• Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer.
• LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine.
• Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors.
• Inhibitory activity of a ceramide library on interleukin-4 production from activated T cells.
• A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
• Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
• Effect of the macrolide antibacterial drug, tylosin, on TNBS-induced colitis in the rat.
• Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.
• Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.
• A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.
• Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
• Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro.
• Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation.
• Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
• A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1.
• Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation.
• Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma.
• Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study.
• Quinolinium salt as a potent inhibitor of lymphocyte apoptosis.
• Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
• Effects of PRI-2191--a low-calcemic analog of 1,25-dihydroxyvitamin D3 on the seizure-induced changes in brain gene expression and immune system activity in the rat.
• Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase.
• Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents.
• Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase.
• In silico ADME modelling: prediction models for blood-brain barrier permeation using a systematic variable selection method.
• Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats.
• Attenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigs.
• Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling.
• Protective mechanisms of a metalloporphyrinic peroxynitrite decomposition catalyst, WW85, in rat cardiac transplants.
• A novel effect for annexin 1-derived peptide ac2-26: reduction of allergic inflammation in the rat.
• Target-directed proteolysis at the ribosome.
• Characterization of a monoclonal antibody that antagonizes the function of human endostatin.
• Cyclosporin A is a broad-spectrum multidrug resistance modulator.
• Prior elevation of IL-18 promotes rapid early IFN-gamma production during staphylococcal infection.
• Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3.
• Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice.
• Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage.
• Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress.
• Recognition of bacterial glycosphingolipids by natural killer T cells.
• Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.
• Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats.
• Protection against bleomycin-induced lung injury by IL-18 in mice.
• Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations.
• Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells.
• TIM-1 induces T cell activation and inhibits the development of peripheral tolerance.
• Study on hepatoprotective effect of peptide S-8300 from shark liver.
• A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.
• Stimulation of CD95-induced apoptosis in T-cells by a subtype specific neutral sphingomyelinase inhibitor.
• Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
• The pyrimidinergic P2Y6 receptor mediates a novel release of proinflammatory cytokines and chemokines in monocytic cells stimulated with UDP.
• Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.
• Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.
• ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.
• Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
• Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
• Druggability indices for protein targets derived from NMR-based screening data.
• High-throughput lipophilicity measurement with immobilized artificial membranes.
• Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice.
• Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice.
• alpha-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation.
• Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors.
• Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis.
• Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer.
• Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen.
• Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies.
• Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
• Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
• Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.
• Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3.
• Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of aciclovir in rats.
• The effect of montelukast on eosinophil apoptosis: induced sputum findings of patients with mild persistent asthma.
• Benzothiazolium compounds: novel classes of inhibitors that suppress the nitric oxide production in RAW264.7 cells stimulated by LPS/IFNgamma.
• Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate.
• PG490-88, a new immunosuppressant, effectively prevents acute and chronic rejection in rat renal allografts.
• A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts.
• Beneficial effect of FR183998, a Na+/H+ exchanger inhibitor, on porcine pancreas allotransplantation retrieved from non-heart-beating donors.
• Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight.
• Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation.
• The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy.
• Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models.
• Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).
• Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain.
• p53 is a suppressor of inflammatory response in mice.
• Vav proteins are required for B-lymphocyte responses to LPS.
• Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12.
• Peptide-based therapeutic vaccines for allergic and autoimmune diseases.
• Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10.
• Ipr1 gene mediates innate immunity to tuberculosis.
• Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
• IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates.
• A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.
• Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation.
• Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
• Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
• Reduction of arthritis severity in protease-activated receptor-deficient mice.
• Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
• Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
• JTP-27536 [(+)-1,3-dihydroxy-2-hydroxymethylpropyl-2-ammonium 2-[(R)-3-cyclo-hexyl-1-phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydrate], a novel inhibitor of immunoglobulins and interleukin-5 with anti-inflammatory properties in mouse allergic dermatitis model.
• Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
• Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
• TX-1877, a bifunctional hypoxic cell radiosensitizer, enhances anticancer host response: immune cell migration and nitric oxide production.
• An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
• Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
• Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder.
• The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro.
• The effects of anti-histone H1 antibody on immune cells responsible for rejection reaction.
• Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
• Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.
• An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
• Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis.
• Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
• Stable antibody expression at therapeutic levels using the 2A peptide.
• Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
• Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression.
• The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
• 2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.
• The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
• Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
• C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation.
• Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
• In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
• The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
• A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
• Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
• Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor.
• Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
• An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells.
• Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation.
• Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
• Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.
• Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo.
• Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis.
• Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines.
• Role of interleukin-6 in mortality from and physiologic response to sepsis.
• Interleukin-15 enhances innate and adaptive immune responses to blood-stage malaria infection in mice.
• Interleukin-6 depletion selectively improves hepatic insulin action in obesity.
• Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands.
• Enhancement of fentanyl antinociception by subeffective doses of nitroparacetamol (NCX-701) in acute nociception and in carrageenan-induced monoarthritis.
• A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report.
• Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
• Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
• Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
• Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile.
• Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
• A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.
• Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness.
• TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage.
• mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
• Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury.
• Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.
• Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia.
• Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
• Immunomodulatory activities of small host defense peptides.
• Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
• Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver.
• Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.
• Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.
• Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
• Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.
• Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.
• Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design.
• Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
• Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis.
• Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
• Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists.
• Identification of chemokine receptor CCR4 antagonist.
• Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2).
• Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
• Effective antitumour mono- and combination therapy by gene delivery of angiostatin-like molecule and interleukin-12 in a murine hepatoma model.
• Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.
• Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis.
• Identification of novel cytosolic phospholipase A(2)s, murine cPLA(2){delta}, {epsilon}, and {zeta}, which form a gene cluster with cPLA(2){beta}.
• Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes.
• Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
• Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
• Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice.
• Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
• A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts.
• Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1.
• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.
• A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential.
• The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.
• A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial.
• Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
• The evaluation of 2,8-disubstituted benzoxazinone derivatives as anti-inflammatory and anti-platelet aggregation agents.
• Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy.
• IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.
• Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease.
• Cutting edge: the SLAM family receptor Ly108 controls T cell and neutrophil functions.
• A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.
• Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis.
• The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle.
• Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.
• Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice.
• Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.
• Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine.
• Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages.
• An international cohort study of cancer in systemic lupus erythematosus.
• Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice.
• Panorama Ab Microarray Cell Signaling kit: a unique tool for protein expression analysis.
• Design, construction, and characterization of a large synthetic human antibody phage display library.
• Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction.
• Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
• Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma.
• Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.
• Expression of P2X4 receptor by lesional activated microglia during formalin-induced inflammatory pain.
• Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis.
• Intestinal inflammation induces adaptation of P-glycoprotein expression and activity.
• Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
• Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
• Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
• Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
• Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
• The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues.
• Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.
• Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors.
• Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
• Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
• Viral expression of CCL2 is sufficient to induce demyelination in RAG1-/- mice infected with a neurotropic coronavirus.
• Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.
• Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI).
• Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
• Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries.
• Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.
• Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction.
• Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis.
• Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.
• Prevention of hemorrhagic shock-induced lung injury by heme arginate treatment in rats.
• Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
• I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss.
• A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo.
• Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
• Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption.
• CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis.
• Dual impact of a nitric oxide donor, GEA 3175, in human pulmonary smooth muscle.
• Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
• SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis.
• In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis.
• Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation.
• Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
• Antigen-specific CD4+ T cells drive airway smooth muscle remodeling in experimental asthma.
• Dendritic cell immunotherapy with poly(D,L-2,4-diaminobutyric acid)-mediated intratumoral delivery of the interleukin-12 gene suppresses tumor growth significantly.
• CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.
• Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
• In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation.
• Hepatocyte growth factor facilitates the repair of large colonic ulcers in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats.
• Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer.
• A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles.
• The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats.
• Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
• Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
• Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
• A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections.
• Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.
• Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.
• Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity.
• Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
• Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.
• Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.
• Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.
• Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.
• Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity.
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
• Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.
• Affinity selection to papain yields potent peptide inhibitors of cathepsins L, B, H, and K.
• Potentiation of beta-adrenoceptor function in bovine tracheal smooth muscle by inhibition of protein kinase C.
• 1Alpha,25-dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells.
• Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.
• Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice.
• Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.
• Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.
• Analysis of a 17-amino acid residue, virus-neutralizing microantibody.
• Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor.
• 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
• Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum.
• Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils.
• Autoantigens act as tissue-specific chemoattractants.
• A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity.
• A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody.
• Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice.
• Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles.
• The malononitrilamide FK778 inhibits activation of NF-kappaB in human dendritic cells.
• A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
• Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
• G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes.
• Structural bioinformatics-based design of selective, irreversible kinase inhibitors.
• Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction.
• The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway.
• Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis.
• ErbB2 activity is required for airway epithelial repair following neutrophil elastase exposure.
• Phthalazine PDE IV inhibitors: conformational study of some 6-methoxy-1,4-disubstituted derivatives.
• Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages.
• Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.
• RON-regulated innate immunity is protective in an animal model of multiple sclerosis.
• Biological properties of a human compact anti-ErbB2 antibody.
• A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.
• A role for ADAM12 in breast tumor progression and stromal cell apoptosis.
• Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
• Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector.
• Design of effective immunotherapy for human autoimmunity.
• Treatment of severe autoimmune disease by stem-cell transplantation.
• A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
• Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses.
• Cannabinoid influence on cytokine profile in multiple sclerosis.
• The structure of interleukin-2 complexed with its alpha receptor.
• Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis.
• Interleukin-4 can be a key positive regulator of inflammatory arthritis.
• The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models.
• Amelioration of rat adjuvant-induced arthritis by Met-RANTES.
• Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice.
• Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.
• Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2.
• Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease.
• Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release.
• First study of infliximab treatment in patients with chronic obstructive pulmonary disease.
• NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis.
• The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung.
• Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation.
• High-throughput screening of interactions between G protein-coupled receptors and ligands using confocal optics microscopy.
• FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
• Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma.
• Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation.
• Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
• Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis.
• Topical inhibition of nuclear factor-kappaB enhances reduction in lung edema by surfactant in a piglet model of airway lavage.
• Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
• Preparation and characterization of a monoclonal antibody against mannoprotein of Candida albicans.
• The non-MHC quantitative trait locus Cia5 contains three major arthritis genes that differentially regulate disease severity, pannus formation, and joint damage in collagen- and pristane-induced arthritis.
• Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
• The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease.
• Stem cell division is regulated by the microRNA pathway.
• Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12.
• Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.
• 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
• Th1-orientated immunological properties of the bacterial extract OM-85-BV.
• Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
• High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod.
• Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins.
• Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
• Characterization of GPRA, a novel G protein-coupled receptor related to asthma.
• Leukotriene inhibitors in combination with steroids: potential role in the development of primary bacterial peritonitis.
• MCI-186 (edaravone), a free radical scavenger, attenuates hepatic warm ischemia-reperfusion injury in rats.
• Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.
• The protective effect of alpha-crystallin against acute inflammation in mice.
• IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression.
• Prevention of NF-kappaB activation in vivo by a cell-permeable NF-kappaB inhibitor peptide.
• Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
• APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.
• New amides of 5-acylamino-3-methyl-4-isothiazolecarboxylic acid and their immunotropic activity.
• Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
• Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
• Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886.
• Syntheses of NAMDA derivatives inhibiting NO production in BV-2 cells stimulated with lipopolysaccharide.
• Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo.
• Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer.
• Heme oxygenase-1 inhibits cigarette smoke-induced increase in the tracheal mucosal permeability in guinea pigs in vivo.
• Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases.
• Enhancement of cell mediated immune responses using lipid depleted lentivirus as immunogen: a novel approach for inducing recognition of new viral epitopes.
• (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
• Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits.
• The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.
• Evasion of Toll-like receptor 5 by flagellated bacteria.
• Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
• Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
• Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.
• Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.
• Investigating the role of relaxin in the regulation of airway fibrosis in animal models of acute and chronic allergic airway disease.
• Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions.
• A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene.
• Toll-like receptors on tumor cells facilitate evasion of immune surveillance.
• Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines.
• Human adaptive immune system Rag2-/-gamma(c)-/- mice.
• Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
• IL-24 inhibits the growth of hepatoma cells in vivo.
• The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.
• Rhodanine derivatives as inhibitors of JSP-1.
• A systematic approach for comprehensive T-cell epitope discovery using peptide libraries.
• Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells.
• Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.
• Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
• Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1.
• A prothrombin activator (Lopap) modulating inflammation, coagulation and cell survival mechanisms.
• Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: structure-activity relationship and molecular mechanisms involved.
• Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.
• Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus.
• Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.
• Amphiphilic pyridinium salts block TNF alpha/NF kappa B signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells.
• Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.
• Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli.
• Anti-inflammatory and antioxidative effects of propofol on lipopolysaccharide-activated macrophages.
• Antisense RNA to inducible nitric oxide synthase reduces cytokine-mediated brain endothelial cell death.
• A novel pathophysiological mechanism for osteoporosis suggested by an in vivo gene expression study of circulating monocytes.
• P2 receptor blockade attenuates fever and cytokine responses induced by lipopolysaccharide in rats.
• CXCL12 (SDF-1) and CXCL13 (BCA-1) chemokines significantly induce proliferation and collagen type I expression in osteoblasts from osteoarthritis patients.
• Attenuation of graft injury in porcine liver transplantation from non-heart beating donor by FR167653.
• Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
• The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection.
• Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.
• Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies.
• Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.
• Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]
• Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group.
• Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines.
• Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2'R,3'S)-3'-phenylisoserinate) and N-benzoyl-(2'R,3'S)-3'-phenylisoserine.
• Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis.
• Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis.
• Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines.
• A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.
• Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
• Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.
• Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
• Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance.
• beta2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation.
• 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
• Expression profiles and functional analyses of Wnt-related genes in human joint disorders.
• 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
• Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin.
• Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.
• Streptozotocin-induced diabetic nephropathy in rats: the role of inflammatory cytokines.
• Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study.
• Genetic deletion or antibody blockade of alpha1beta1 integrin induces a stable plaque phenotype in ApoE-/- mice.
• Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
• Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome.
• The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
• Effect of adrenomedullin administration on acetic acid-induced colitis in rats.
• Design and synthesis of low molecular weight compounds with complement inhibition activity.
• Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats.
• Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
• Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.
• Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.
• Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
• Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.
• A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice.
• Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation.
• Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice.
• Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
• Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.
• Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.
• Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules.
• VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
• Pharmacologic preconditioning effects: prostaglandin E1 induces heat-shock proteins immediately after ischemia/reperfusion of the mouse liver.
• Second-generation beta-oxidation resistant 3-oxa-lipoxin A4 analogs.
• Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma.
• Monocyte suppressing action of fenofibrate.
• Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial.
• Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
• Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
• Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
• Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells.
• Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death.
• Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts.
• Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in rats.
• Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy.
• A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat.
• Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes.
• Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.
• Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
• Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation.
• Regional assessment of articular cartilage gene expression and small proteoglycan metabolism in an animal model of osteoarthritis.
• Gene expression profile and synovial microcirculation at early stages of collagen-induced arthritis.
• Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations.
• Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
• Control of T helper 2 cell function and allergic airway inflammation by PKCzeta.
• Daclizumab to prevent rejection after cardiac transplantation.
• Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease.
• Harmful and protective roles of neutrophils in sepsis.
• Rho-associated kinase modulates myocardial inflammatory cytokine responses.
• The molecular basis for coxib inhibition of p38alpha MAP kinase.
• Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives.
• QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors.
• CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
• Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle.
• Proasthmatic effects and mechanisms of action of the dust mite allergen, Der p 1, in airway smooth muscle.
• Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens.
• Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21.
• Anti-CD11d antibody treatment reduces free radical formation and cell death in the injured spinal cord of rats.
• Cutaneous side-effects of kinase inhibitors and blocking antibodies.
• Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor.
• Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.
• Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridine series.
• A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors.
• Inhibition of obliterative airway disease development following heterotopic murine tracheal transplantation by costimulatory molecule blockade using anti-CD40 ligand alone or in combination with donor bone marrow.
• Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation.
• Development of a functional cDNA array for evaluation of the Th1/Th2 balance.
• The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation.
• Soluble epoxide hydrolase is a therapeutic target for acute inflammation.
• Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis.
• Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
• Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils.
• Transforming growth factor-beta1 drives airway remodeling in cigarette smoke-exposed tracheal explants.
• Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers.
• A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.
• Expression of mediators of renal injury in the remnant kidney of ROP mice is attenuated by cyclooxygenase-2 inhibition.
• P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin.
• The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.
• Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.
• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
• Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
• Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study.
• Treatment of orbital myositis with adalimumab (Humira).
• Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function.
• Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats.
• S-2474, a novel nonsteroidal anti-inflammatory drug, rescues cortical neurons from human group IIA secretory phospholipase A(2)-induced apoptosis.
• Capsazepine, a vanilloid receptor antagonist, inhibits allergen-induced tracheal contraction.
• Protective role for cytosolic phospholipase A2alpha in autoimmune diabetes of mice.
• Functional expression of the P2Y14 receptor in murine T-lymphocytes.
• Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures.
• Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
• Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts.
• Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.
• Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study.
• Inhibitory effect of whole bee venom in adjuvant-induced arthritis.
• Adamantyl cannabinoids: a novel class of cannabinergic ligands.
• Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase.
• New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
• Nonionic amphiphilic block copolymers promote gene transfer to the lung.
• Whole genome association study of rheumatoid arthritis using 27 039 microsatellites.
• The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
• Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation.
• In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1.
• Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
• Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents.
• Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma.
• Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs.
• In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.
• IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling.
• Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice.
• A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation.
• Mucosal B cell deficiency in IgA-/- mice abrogates the development of allergic lung inflammation.
• Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
• Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide.
• Selective inhibition of Fcepsilon RI-mediated mast cell activation by a truncated variant of Cbl-b related to the rat model of type 1 diabetes mellitus.
• Effects of repeated antigen exposure on endothelin-1-induced bronchial smooth muscle contraction and activation of RhoA in sensitized rats.
• Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist.
• Identification of potent and selective MMP-13 inhibitors.
• Regulation of neuronal P53 activity by CXCR 4.
• Group IB secretory phospholipase A2 stimulates leukotriene B4 production by a unique mechanism in human neutrophils.
• HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo.
• Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3.
• Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis.
• HIF-1alpha expression regulates the bactericidal capacity of phagocytes.
• HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.
• Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients.
• In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis.
• Up-regulation of cyclooxygenase-2 during acute human renal allograft rejection.
• Effects of the terminal charges in human neutrophil alpha-defensin 2 on its bactericidal and membrane activity.